Contribution of Nasal High Flow in Pneumology Assessed in Acid-Free Hypercapnic Acute Respiratory Failure

Launched by CENTRE HOSPITALIER INTERCOMMUNAL DE TOULON LA SEYNE SUR MER · Aug 18, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the use of a treatment called Nasal High Flow therapy for patients who are experiencing a type of breathing problem known as Hypercapnic Acute Respiratory Failure. This condition means that there is too much carbon dioxide in the blood, which can happen for various reasons, such as chronic lung diseases. The researchers believe that using Nasal High Flow therapy, in addition to standard treatments, may help improve the care of these patients. The trial is currently looking for participants who are 18 years or older and have been diagnosed with this respiratory issue within the last 24 hours, among other specific criteria.

Eligible participants should be those who have high levels of carbon dioxide but are not showing signs of severe respiratory distress that would require more invasive treatments. If you or someone you know meets these criteria, you could expect to receive the Nasal High Flow therapy alongside regular care for your breathing condition. It's important to note that certain health issues and situations, like being pregnant or participating in other research studies, might prevent someone from joining this trial. If you have any further questions about the trial or your eligibility, don't hesitate to reach out to the study team for more information.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Major patient ≥ 18 years old
• • Medical diagnosis of Acute Respiratory Failure less than 48 hours
• • With partial pressure of carbon dioxide (PaCO2) \> 45 and pH \> 7.35 for less than 48 hours, with no indication of Non-Invasive Ventilation (NIV) placement
• • Underlying terrain of known or unknown chronic respiratory pathology (may be unknown at time of diagnosis) Examples : COPD, Bronchiectasis, Pulmonary fibrosis, asthma, sequelae pathologies ...
• • All etiologies (infectious, cardiac decompensation, trauma, etc.)
• • Having given informed consent
• • Patient under a social security scheme
• • Possibility to include a patient having already been included in the study but suffering from a new episode of hypercapnic non acidic Acute Respiratory Failure
• Exclusion Criteria:
• • Restrictive chronic neuromuscular or kyphoscoliotic respiratory insufficiencies
• • Drug-induced Acute respiratory failure
• • Pneumothorax (X-ray pulmonary detachment)
• • Oxygen poisoning
• • Severe Acute Respiratory Syndrome (SARS) Coronavirus 2 (COVII) Pneumonia
• • Tracheostomy
• • Prior treatment with chronic or initiated NIV just prior to treatment (e.g. Intensive Care Unit)
• • Respiratory Severity Criteria for Resuscitation Management
• • Agitation or non-cooperation
• • Pregnancy or breastfeeding
• • Person participating in other biomedical research
• • Any other reason that the investigator believes may interfere with the evaluation of the study objectives
• • Person under judicial protection (guardianship, curatorship)
• • Person deprived of liberty by a judicial or administrative decision